List of Tables
Table 1. Chronic Granulomatous Disease (CGD) Treatment Market Trends
Table 2. Chronic Granulomatous Disease (CGD) Treatment Market Drivers & Opportunity
Table 3. Chronic Granulomatous Disease (CGD) Treatment Market Challenges
Table 4. Chronic Granulomatous Disease (CGD) Treatment Market Restraints
Table 5. Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Chronic Granulomatous Disease (CGD) Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Chronic Granulomatous Disease (CGD) Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Chronic Granulomatous Disease (CGD) Treatment
Table 10. Global Chronic Granulomatous Disease (CGD) Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Clinigen Group plc Basic Information List
Table 32. Clinigen Group plc Description and Business Overview
Table 33. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Clinigen Group plc (2019-2024)
Table 35. Clinigen Group plc Recent Developments
Table 36. Orchard Therapeutics plc2032 Basic Information List
Table 37. Orchard Therapeutics plc2032 Description and Business Overview
Table 38. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Orchard Therapeutics plc2032 (2019-2024)
Table 40. Orchard Therapeutics plc2032 Recent Developments
Table 41. Horizon Therapeutics plc Basic Information List
Table 42. Horizon Therapeutics plc Description and Business Overview
Table 43. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Horizon Therapeutics plc (2019-2024)
Table 45. Horizon Therapeutics plc Recent Developments
Table 46. ViroMed. Co. Ltd Basic Information List
Table 47. ViroMed. Co. Ltd Description and Business Overview
Table 48. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of ViroMed. Co. Ltd (2019-2024)
Table 50. ViroMed. Co. Ltd Recent Developments
Table 51. Bellicum Pharmaceuticals, Inc Basic Information List
Table 52. Bellicum Pharmaceuticals, Inc Description and Business Overview
Table 53. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Bellicum Pharmaceuticals, Inc (2019-2024)
Table 55. Bellicum Pharmaceuticals, Inc Recent Developments
Table 56. Pfizer Inc Basic Information List
Table 57. Pfizer Inc Description and Business Overview
Table 58. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Pfizer Inc (2019-2024)
Table 60. Pfizer Inc Recent Developments
Table 61. Hoffmann-La Roche Ltd Basic Information List
Table 62. Hoffmann-La Roche Ltd Description and Business Overview
Table 63. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Hoffmann-La Roche Ltd (2019-2024)
Table 65. Hoffmann-La Roche Ltd Recent Developments
Table 66. Novartis AG Basic Information List
Table 67. Novartis AG Description and Business Overview
Table 68. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Novartis AG (2019-2024)
Table 70. Novartis AG Recent Developments
Table 71. Lonza Basic Information List
Table 72. Lonza Description and Business Overview
Table 73. Lonza Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Lonza (2019-2024)
Table 75. Lonza Recent Developments
Table 76. GlaxoSmithKline plc Basic Information List
Table 77. GlaxoSmithKline plc Description and Business Overview
Table 78. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of GlaxoSmithKline plc (2019-2024)
Table 80. GlaxoSmithKline plc Recent Developments
Table 81. Eli Lilly and Company Basic Information List
Table 82. Eli Lilly and Company Description and Business Overview
Table 83. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Eli Lilly and Company (2019-2024)
Table 85. Eli Lilly and Company Recent Developments
Table 86. Johnson & Johnson Services, Inc Basic Information List
Table 87. Johnson & Johnson Services, Inc Description and Business Overview
Table 88. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Johnson & Johnson Services, Inc (2019-2024)
Table 90. Johnson & Johnson Services, Inc Recent Developments
Table 91. Merck KGaA Basic Information List
Table 92. Merck KGaA Description and Business Overview
Table 93. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Merck KGaA (2019-2024)
Table 95. Merck KGaA Recent Developments
Table 96. Key Raw Materials Lists
Table 97. Raw Materials Key Suppliers Lists
Table 98. Chronic Granulomatous Disease (CGD) Treatment Downstream Customers
Table 99. Chronic Granulomatous Disease (CGD) Treatment Distributors List
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
Table 103. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Chronic Granulomatous Disease (CGD) Treatment Product Picture
Figure 2. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Chronic Granulomatous Disease (CGD) Treatment Report Years Considered
Figure 5. Global Chronic Granulomatous Disease (CGD) Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023
Figure 7. Chronic Granulomatous Disease (CGD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. X-Linked Chronic Granulomatous Disease Picture
Figure 9. Autosomal Recessive Chronic Granulomatous Disease Picture
Figure 10. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Neutrophil Function Tests
Figure 13. Product Picture of Genetic Testing
Figure 14. Product Picture of Prenatal Testing
Figure 15. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 17. North America Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 18. North America Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 19. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 20. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 21. Asia Pacific Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 22. Asia Pacific Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 23. South America Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 24. South America Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 25. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 26. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 27. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value (%), (2019-2030)
Figure 28. United States Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 29. United States Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 30. United States Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 31. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 32. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 33. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 34. China Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 35. China Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 36. China Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 37. Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 38. Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 39. Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 40. South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 41. South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 42. South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 43. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 45. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 46. India Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 47. India Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 48. India Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 49. Chronic Granulomatous Disease (CGD) Treatment Industrial Chain
Figure 50. Chronic Granulomatous Disease (CGD) Treatment Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation